"Drug-Eluting Stents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Stents that are covered with materials that are embedded with chemicals that are gradually released into the surrounding milieu.
| Descriptor ID |
D054855
|
| MeSH Number(s) |
E07.695.750.500
|
| Concept/Terms |
Drug-Eluting Stents- Drug-Eluting Stents
- Drug Eluting Stents
- Drug-Eluting Stent
- Stent, Drug-Eluting
- Stents, Drug-Eluting
- Stents, Drug Eluting
Drug-Coated Stents- Drug-Coated Stents
- Drug Coated Stents
- Drug-Coated Stent
- Stent, Drug-Coated
- Stents, Drug-Coated
- Stents, Drug Coated
|
Below are MeSH descriptors whose meaning is more general than "Drug-Eluting Stents".
Below are MeSH descriptors whose meaning is more specific than "Drug-Eluting Stents".
This graph shows the total number of publications written about "Drug-Eluting Stents" by people in this website by year, and whether "Drug-Eluting Stents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2010 | 6 | 0 | 6 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 4 | 1 | 5 |
| 2015 | 4 | 2 | 6 |
| 2016 | 14 | 3 | 17 |
| 2017 | 10 | 0 | 10 |
| 2018 | 9 | 0 | 9 |
| 2019 | 6 | 4 | 10 |
| 2020 | 10 | 1 | 11 |
| 2021 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug-Eluting Stents" by people in Profiles.
-
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024 Sep 07; 404(10456):937-948.
-
Stent Failure After Percutaneous Coronary Intervention in Diabetes?Mellitus: Does Glycemic Control Matter? J Am Coll Cardiol. 2024 Jul 16; 84(3):273-275.
-
Prognostic impact of peripheral artery disease in patients with and without high bleeding risk undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(3):425-434.
-
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? Med Clin North Am. 2024 May; 108(3):539-551.
-
Prognostic impact of in-stent restenosis in normal weight, overweight, and obese patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(2):260-267.
-
Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2023 11 16; 383:e077848.
-
Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More. JACC Cardiovasc Interv. 2022 06 13; 15(11):1164-1166.
-
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention. 2022 Mar 18; 17(16):1330-1339.
-
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022 02 14; 15(3):282-293.
-
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021 12 01; 42(45):4683-4693.